Legend Biotech Corp
LEGN Nasdaq Pharmaceutical Preparations Financials FY2018–FY2025
Legend Biotech Corp had $1.0B of revenue in fiscal 2025, up 64.0% on the year before. Over five years, revenue changed +68.8% a year on average.
- Today
- 3.8%
- Previous close
- $23.40
- Market cap
- $4.5B
- P/E
- —
- Day range
-
$22.88 $24.42
- 52-week range
-
$16.65 $36.28
Last close · Nov 9, 2026
$24.29
−$7.51 (−23.62%) past year
Latest quarter
Q4 '25 results
+64.3%
Revenue vs Q4 '24
Quarter ended December 31, 2025
See every quarter| Line | Q4 '24 | Q4 '25 | Change (y/y) |
|---|---|---|---|
| Revenue | $187M | $306M | 64.3% |
| Net income | $26.3M | −$30.8M | 217.2% |
| Diluted EPS | $0.14 | −$0.18 | 228.6% |
| Operating margin | −42.5% | −6.4% | 36.1 pts |
| Free cash flow | −$84.4M | −$24.6M | — |
Key numbers
Key numbers, fiscal 2025
Revenue and margins
Revenue and margins
KIRA summarises the numbers
-
Legend Biotech Corp had $1.0B of revenue in fiscal 2025, up 64.0% on the year before.
Over five years, revenue changed +68.8% a year on average.
-
Its operating margin was −13.3%, up 36.1 pts: of every 100 in sales, about −13 is left after running the business.
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Net income
Net income and earnings per share
Loss periods are shown in red.
KIRA summarises the numbers
-
Legend Biotech Corp lost $297M in fiscal 2025.
Net income
Net income
Diluted EPS
Diluted EPS
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Cash flow
Cash flow
Cash from operations minus capital spending.
KIRA summarises the numbers
-
Free cash flow was −$129M in fiscal 2025, −12.5% of revenue.
At that burn of $129M a year, its $902M of cash and short-term investments would last about 7.0 years.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Dividends and buybacks
Dividends, buybacks and share count
Dividends and buybacks
Diluted shares outstanding (annual)
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Insider trades
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
KIRA summarises the numbers
-
In the last 12 months, insiders sold $0.6M of shares on the open market and bought none.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.6M
4 insiders
Of sales under plans
0%
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 29, 2026 | Corazon (Corsee) D. SandersDirector | Sold | 27,370 | $9.46 | $0.3M | Form 4 |
| Sep 21, 2026 | Carlos E SantosChief Financial Officer | Sold | 5,430 | $9.14 | $0.0M | Form 4 |
| Jun 30, 2026 | Patrick John CaseyDirector | Sold | 6,000 | $14.80 | $0.1M | Form 4 |
| Jun 25, 2026 | Ying HuangChief Executive Officer, Director | Sold | 5,566 | $14.78 | $0.1M | Form 4 |
| Mar 25, 2026 | Ying HuangChief Executive Officer, Director | Sold | 9,936 | $8.77 | $0.1M | Form 4 |
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Balance sheet
Balance sheet
Cash, debt and the ratios that show how comfortably Legend Biotech Corp can carry it.
KIRA summarises the numbers
-
Legend Biotech Corp has $583M more cash than debt.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $689M | $786M | $1.3B | $287M | $902M |
| Debt incl. finance leases | $120M | $250M | $250M | $250M | $319M |
| Debt / equity | 0.2x | 0.3x | 0.2x | 0.2x | 0.3x |
| Interest coverage | — | — | −24.2x | −14.3x | −6.4x |
| Current ratio | 4.1x | 3.7x | 6.9x | 4.6x | 2.0x |
| Quick ratio | 4.1x | 3.7x | 6.8x | 4.5x | 1.9x |
| Total assets | $1.1B | $1.3B | $1.8B | $1.7B | $1.7B |
| Total liabilities | $354M | $587M | $597M | $630M | $732M |
| Shareholders' equity | $766M | $744M | $1.3B | $1.0B | $1.0B |
| Net debt (− = net cash) | −$569M | −$536M | −$1.0B | −$36.7M | −$583M |
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Returns on capital
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
KIRA summarises the numbers
-
Its return on capital was −25.7%: every 100 invested in the business earned about −26 in a year.
Return on capital, equity and assets (annual)
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
F-score
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
KIRA summarises the numbers
-
Legend Biotech Corp passes 2 of 9 financial health tests (Piotroski F-score).
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| F-score | 2 / 8 | 3 / 9 | 6 / 9 | 4 / 9 | 2 / 9 |
| Accruals ratio | −22.3% | −20.0% | −7.9% | −1.9% | −11.6% |
| Altman Z'' | — | — | — | — | — |
| Net income is positive | ✕ | ✕ | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ | ✕ | ✕ |
| Return on assets rose | ✓ | ✓ | ✓ | ✓ | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | ✕ | ✓ | ✕ | ✕ |
| Current ratio rose | ✕ | ✕ | ✓ | ✕ | ✕ |
| Share count didn't rise | ✕ | ✕ | ✕ | ✕ | ✕ |
| Gross margin rose | ✕ | ✕ | ✓ | ✓ | ✕ |
| Revenue rose relative to assets | ✕ | ✓ | ✓ | ✓ | ✓ |
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
All figures
8 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $49.1M | $60.0M | $75.0M | $68.8M | $117M | $285M | $627M | $1.0B |
| Gross profit | — | — | $75.0M | $68.8M | $51.6M | $141M | $411M | $632M |
| Research and development | $60.6M | $162M | $232M | $313M | $336M | $382M | $414M | $415M |
| Operating income | — | — | — | — | — | −$528M | −$310M | −$137M |
| Interest expense | $0.1M | $0.2M | $4.2M | $0.9M | $10.8M | $21.8M | $21.6M | $21.4M |
| Pretax income | −$1.6M | −$127M | −$308M | −$407M | −$446M | −$520M | −$158M | −$283M |
| Income tax | $1.2M | −$25.7M | −$41.9M | −$3.6M | $0.6M | −$1.9M | $18.9M | $14.2M |
| Net income | −$2.8M | −$102M | −$266M | −$404M | −$446M | −$518M | −$177M | −$297M |
| Net income to common | −$2.8M | −$102M | −$266M | −$404M | −$446M | −$518M | −$177M | — |
| Diluted EPS | −$0.02 | −$1.02 | −$2.26 | −$2.86 | −$2.80 | −$2.94 | −$0.96 | −$1.62 |
| Diluted shares | 0.10B | 0.10B | 0.12B | 0.14B | 0.16B | 0.18B | 0.18B | 0.18B |
| Cash flow | ||||||||
| Cash from operations | $308M | −$83.1M | −$223M | −$198M | −$201M | −$393M | −$144M | −$100M |
| Capital expenditure | $21.0M | $26.8M | $26.3M | $42.2M | $20.9M | $20.1M | $14.1M | $28.6M |
| Free cash flow | $287M | −$110M | −$249M | −$241M | −$222M | −$413M | −$158M | −$129M |
| Stock-based compensation | $0.7M | $1.3M | $4.8M | $20.2M | $34.3M | $47.7M | $68.9M | $64.6M |
| Balance sheet | ||||||||
| Cash and short-term investments | $210M | $83.4M | $456M | $689M | $786M | $1.3B | $287M | $902M |
| Total debt | — | — | — | $120M | $250M | $250M | $250M | $319M |
| Current assets | — | $207M | $594M | $950M | $1.1B | $1.5B | $1.3B | $1.2B |
| Current liabilities | — | $128M | $116M | $229M | $298M | $216M | $278M | $636M |
| Inventory | — | $1.2M | $1.8M | $1.7M | $10.4M | $19.4M | $23.9M | $32.0M |
| Property and equipment, net | $28.2M | $45.2M | $72.3M | $103M | $105M | $109M | $99.3M | $116M |
| Intangible assets | — | $0.5M | $2.9M | $4.7M | $3.4M | $4.1M | $2.2M | $1.9M |
| Total assets | — | $288M | $722M | $1.1B | $1.3B | $1.8B | $1.7B | $1.7B |
| Total liabilities | — | $411M | $124M | $354M | $587M | $597M | $630M | $732M |
| Shareholders' equity | $253M | −$123M | $598M | $766M | $744M | $1.3B | $1.0B | $1.0B |
| Margins | ||||||||
| Gross margin | — | — | 100.0% | 100.0% | 44.1% | 49.4% | 65.5% | 61.4% |
| Operating margin | — | — | — | — | — | −185.2% | −49.3% | −13.3% |
| Net margin | −5.7% | −169.4% | −355.2% | −586.4% | −381.5% | −181.8% | −28.2% | −28.8% |
| FCF margin | 583.6% | −183.1% | −332.3% | −349.7% | −189.9% | −145.0% | −25.2% | −12.5% |
| Returns | ||||||||
| Return on capital | — | — | — | — | — | −186.5% | −24.4% | −25.7% |
| Return on capital employed | — | — | — | — | — | −32.4% | −22.2% | −12.4% |
| Return on equity | −1.1% | −156.2% | −112.2% | −59.2% | −59.1% | −51.9% | −15.4% | −29.1% |
| Return on assets | — | −35.3% | −52.8% | −43.8% | −36.4% | −32.6% | −10.1% | −17.4% |
| Return on tangible equity | −1.1% | — | −44.8% | −53.0% | −60.2% | −41.5% | −17.0% | −29.7% |
| Growth | ||||||||
| Revenue growth | — | 22.1% | 25.0% | −8.2% | 70.0% | 143.7% | 120.0% | 64.0% |
| FCF growth | — | −138.3% | — | — | — | — | — | — |
| Share count change | — | 0.0% | 18.2% | 19.2% | 12.9% | 10.7% | 3.8% | 0.8% |
| Financial health | ||||||||
| Debt / equity | — | — | — | 0.2x | 0.3x | 0.2x | 0.2x | 0.3x |
| Interest coverage | — | — | — | — | — | −24.2x | −14.3x | −6.4x |
| Current ratio | — | 1.6x | 5.1x | 4.1x | 3.7x | 6.9x | 4.6x | 2.0x |
| Quick ratio | — | 1.6x | 5.1x | 4.1x | 3.7x | 6.8x | 4.5x | 1.9x |
| Capital allocation | ||||||||
| Capex / revenue | 42.7% | 44.6% | 35.0% | 61.3% | 17.9% | 7.0% | 2.2% | 2.8% |
| Stock comp / revenue | 1.4% | 2.1% | 6.3% | 29.3% | 29.3% | 16.7% | 11.0% | 6.3% |
| Quality scores | ||||||||
| Piotroski F-score | — | — | 2.0 | 2.0 | 3.0 | 6.0 | 4.0 | 2.0 |
| Accruals ratio | — | −6.4% | −8.6% | −22.3% | −20.0% | −7.9% | −1.9% | −11.6% |
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
News and filings
Latest SEC filings
The original documents every number on this page comes from.
KIRA analysis
KIRA’s summary AI analyst
Hi! I read Legend Biotech Corp’s latest annual report (fiscal 2025). Here is what stands out:
Legend Biotech Corp in 30 seconds
Good So-so Weak
Are sales growing?
+64.0%
Yes. Sales grew 64.0% last year.
Does it make a profit?
−28.8%
No. It lost money last year.
How long would its cash last?
7.0 yrs
Comfortably. It burns $129M a year and holds $902M, about 7.0 years at that pace.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
2 / 9
Weak. It passes 2 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Sales and profit
1 2 3 notes
- Legend Biotech Corp had $1.0B of revenue in fiscal 2025, up 64.0% on the year before. Over five years, revenue changed +68.8% a year on average.
- Its operating margin was −13.3%, up 36.1 pts: of every 100 in sales, about −13 is left after running the business.
- Legend Biotech Corp lost $297M in fiscal 2025.
Cash and shareholders
1 2 notes
- Free cash flow was −$129M in fiscal 2025, −12.5% of revenue. At that burn of $129M a year, its $902M of cash and short-term investments would last about 7.0 years.
- In the last 12 months, insiders sold $0.6M of shares on the open market and bought none.
Financial health
1 2 3 notes
- Legend Biotech Corp has $583M more cash than debt.
- Its return on capital was −25.7%: every 100 invested in the business earned about −26 in a year.
- Legend Biotech Corp passes 2 of 9 financial health tests (Piotroski F-score).
Source: SEC EDGAR XBRL filings (CIK 0001801198). Data updated November 9, 2026. Quarterly fourth quarters are the full year minus the first nine months. Per-share figures are per US-listed share (1 ADS = 2 ordinary shares). For information only — not investment advice. Check the original filings before relying on any figure.